Chronic lymphocytic leukemia (CLL) is a kind of slow-growing leukemia that affects developing B-lymphocytes. It is among the most common types of cancer in adults, where the patient does not show the symptoms of the diseases for several years, until the patient is diagnosed with cancer, spread across multiple organs of the body, such as the lymph nodes, liver, and spleen.
According to a 2018 study published in Hematology & Oncology, the global snapshot of the leukemia incidence showed that the men to women patient ratio were 1:4. Australia and America have the highest leukemia rate for men, while Europe has the highest rate for women. Companies have expanded the targeted agents focus on the combinations and sequences which most likely to elicit deep responses with the most curative potential.
This report by Mordor Intelligence provides extensive insights into the current scenario and growth prospects of the market studied. Detailed graphical representations of the pipeline landscape, based on various phases, and the status of clinical trials, across major regions of the world, are given, with data obtained from multiple sources. The report also comprises a list of key sponsors that have pipeline products for the concerned market.
The report will cover analysis on trails and information on key sponsors, companies, and researchers.
Our data collection team builds scientific research models, based on data sourced from various internal databases, primary and secondary researches, and our in-house team of research experts. The pipeline assessment reports are generated based on information procured from various stakeholders, such as sponsors, clinical trial organizations, pharmaceutical companies, government bodies, trade agencies, industry journals, scientific literature databases, investor reports, press release statements, and several other sources. The data generated using secondary research and primary research is validated through discussions with industry KOL’s and C-suite executives. The data presented in the reports is continuously updated to incorporate the most relevant and authentic information to our clients.
2. Research Methodology
3. Disease Epidemiology and Trends
4. Healthcare Expenditure and R&D Trends
5. Executive Summary
6. Clinical Trials Segmentation by Phase
6.1 Phase-III Product Candidates
6.2 Phase-II Product Candidates
6.3 Phase-I Product Candidates
7. Clinical Trials, Segmentation by Status
8. Pipeline Therapeutic Assessment (Infographic Charts and a Brief Description)
8.1. By Clinical Phase and Molecule Type
8.2. By Clinical Phase and Route of Administration
8.3 By Sponsor/Collaborator/Institutions
8.4 By Geography
9. Market Updates
10. Key Sponsor Profiles
11. Sources and Disclaimer
12. About Mordor Intelligence